Zealand Pharma moves into US biotech giant's territory
Zealand Pharma expands its rare disease pre-clinical pipeline to a field dominated by US-based drug group Alexion. Moreover, the Danish biotech company adds a new intestinal disease candidate to its pre-clinical pipeline.
Danish biotech company Zealand Pharma has established a business based on research and development of therapeutic peptides.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo CSO welcomes rival's success
For abonnenter
New candidates in Zealand’s peptide pipeline
For abonnenter
